Schering on possible TRA partners
Executive Summary
Talks with pharmaceutical companies about a potential collaboration on its Phase III thrombin receptor antagonist for atherothrombosis have reached a stumbling block because potential partners have no comparably valuable asset to offer in return, CEO Fred Hassan said during the Morgan Stanley CEOs Unplugged conference Jan. 3. The firm is apparently looking for a quid pro quo relationship: "We are asking them to show us a quid that has the same kind of value so that we can diversify on both sides, and unfortunately for the larger companies they have nothing to show us. That is the biggest challenge," he said. Schering has "talked to practically all the big companies" and remains open to further discussions, he added. Schering announced its interest in partnering on TRA several months ago 1("The Pink Sheet" Oct. 29, 2007, p. 5)...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.